Spero Therapeutics Reschedules Fourth Quarter and Full Year
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,......
Spero Therapeutics to Present at Upcoming Investor
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical......